FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4288987527> ?p ?o ?g. }

• W4288987527 endingPage "100530" @default.
• W4288987527 startingPage "100530" @default.
• W4288987527 abstract "Activation of leukemia inhibitory factor (LIF) is linked to an immunosuppressive tumor microenvironment (TME), with a strong association between LIF expression and tumor-associated macrophages (TAMs). MSC-1 (AZD0171) is a humanized monoclonal antibody that binds with high affinity to LIF, promoting antitumor inflammation through TAM modulation and cancer stem cell inhibition, slowing tumor growth. In this phase I, first-in-human, open-label, dose-escalation study, MSC-1 monotherapy was assessed in patients with advanced, unresectable solid tumors.Using accelerated-titration dose escalation followed by a 3 + 3 design, MSC-1 doses of 75-1500 mg were administered intravenously every 3 weeks (Q3W) until progression or unmanageable toxicity. Additional patients were enrolled in selected cohorts to further evaluate safety, pharmacokinetics (PK), and pharmacodynamics after escalation to the next dose had been approved. The primary objective was characterizing safety and determining the recommended phase II dose (RP2D). Evaluating antitumor activity and progression-free survival (PFS) by RECIST v1.1, PK and immunogenicity were secondary objectives. Exploratory objectives included pharmacodynamic effects on circulating LIF and TME immune markers.Forty-one patients received treatment. MSC-1 monotherapy was safe and well tolerated at all doses, with no dose-limiting toxicities. The maximum tolerated dose was not reached and the RP2D was determined to be 1500 mg Q3W. Almost half of the patients had treatment-related adverse events (TRAEs), with no apparent trends across doses; no patients withdrew due to TRAEs. There were no objective responses; 23.7% had stable disease for ≥2 consecutive tumor assessments. Median PFS was 5.9 weeks; 23.7% had PFS >16 weeks. On-treatment changes in circulating LIF and TME signal transducers and activators of transcription 3 signaling, M1:M2 macrophage populations, and CD8+ T-cell infiltration were consistent with the hypothesized mechanism of action.MSC-1 was very well tolerated across doses, with prolonged PFS in some patients. Biomarker and preclinical data suggest potential synergy with checkpoint inhibitors." @default.
• W4288987527 created "2022-07-31" @default.
• W4288987527 creator A5002903566 @default.
• W4288987527 creator A5003770647 @default.
• W4288987527 creator A5012346804 @default.
• W4288987527 creator A5015509025 @default.
• W4288987527 creator A5025270017 @default.
• W4288987527 creator A5026563473 @default.
• W4288987527 creator A5027996223 @default.
• W4288987527 creator A5033240768 @default.
• W4288987527 creator A5038062596 @default.
• W4288987527 creator A5045742731 @default.
• W4288987527 creator A5054682698 @default.
• W4288987527 creator A5061085235 @default.
• W4288987527 creator A5063961400 @default.
• W4288987527 creator A5064766886 @default.
• W4288987527 creator A5068193017 @default.
• W4288987527 creator A5069817666 @default.
• W4288987527 creator A5070523850 @default.
• W4288987527 creator A5071502090 @default.
• W4288987527 creator A5077565902 @default.
• W4288987527 creator A5079422406 @default.
• W4288987527 creator A5083061371 @default.
• W4288987527 creator A5088186975 @default.
• W4288987527 creator A5088495181 @default.
• W4288987527 date "2022-08-01" @default.
• W4288987527 modified "2023-10-10" @default.
• W4288987527 title "Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors" @default.
• W4288987527 cites W1554341622 @default.
• W4288987527 cites W1557020267 @default.
• W4288987527 cites W1824670638 @default.
• W4288987527 cites W1859966362 @default.
• W4288987527 cites W1977564949 @default.
• W4288987527 cites W1985648424 @default.
• W4288987527 cites W1994006339 @default.
• W4288987527 cites W1995559307 @default.
• W4288987527 cites W1999247596 @default.
• W4288987527 cites W2014139160 @default.
• W4288987527 cites W2018855387 @default.
• W4288987527 cites W2020575974 @default.
• W4288987527 cites W2029669343 @default.
• W4288987527 cites W2037751427 @default.
• W4288987527 cites W2062141980 @default.
• W4288987527 cites W2102456247 @default.
• W4288987527 cites W2119174526 @default.
• W4288987527 cites W2142452362 @default.
• W4288987527 cites W2166693944 @default.
• W4288987527 cites W2167917245 @default.
• W4288987527 cites W2887159463 @default.
• W4288987527 cites W2936366750 @default.
• W4288987527 cites W2951675934 @default.
• W4288987527 cites W2961842639 @default.
• W4288987527 cites W3118966295 @default.
• W4288987527 cites W3193418548 @default.
• W4288987527 cites W4282927325 @default.
• W4288987527 cites W4282979435 @default.
• W4288987527 doi "https://doi.org/10.1016/j.esmoop.2022.100530" @default.
• W4288987527 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35921760" @default.
• W4288987527 hasPublicationYear "2022" @default.
• W4288987527 type Work @default.
• W4288987527 citedByCount "8" @default.
• W4288987527 countsByYear W42889875272022 @default.
• W4288987527 countsByYear W42889875272023 @default.
• W4288987527 crossrefType "journal-article" @default.
• W4288987527 hasAuthorship W4288987527A5002903566 @default.
• W4288987527 hasAuthorship W4288987527A5003770647 @default.
• W4288987527 hasAuthorship W4288987527A5012346804 @default.
• W4288987527 hasAuthorship W4288987527A5015509025 @default.
• W4288987527 hasAuthorship W4288987527A5025270017 @default.
• W4288987527 hasAuthorship W4288987527A5026563473 @default.
• W4288987527 hasAuthorship W4288987527A5027996223 @default.
• W4288987527 hasAuthorship W4288987527A5033240768 @default.
• W4288987527 hasAuthorship W4288987527A5038062596 @default.
• W4288987527 hasAuthorship W4288987527A5045742731 @default.
• W4288987527 hasAuthorship W4288987527A5054682698 @default.
• W4288987527 hasAuthorship W4288987527A5061085235 @default.
• W4288987527 hasAuthorship W4288987527A5063961400 @default.
• W4288987527 hasAuthorship W4288987527A5064766886 @default.
• W4288987527 hasAuthorship W4288987527A5068193017 @default.
• W4288987527 hasAuthorship W4288987527A5069817666 @default.
• W4288987527 hasAuthorship W4288987527A5070523850 @default.
• W4288987527 hasAuthorship W4288987527A5071502090 @default.
• W4288987527 hasAuthorship W4288987527A5077565902 @default.
• W4288987527 hasAuthorship W4288987527A5079422406 @default.
• W4288987527 hasAuthorship W4288987527A5083061371 @default.
• W4288987527 hasAuthorship W4288987527A5088186975 @default.
• W4288987527 hasAuthorship W4288987527A5088495181 @default.
• W4288987527 hasBestOaLocation W42889875271 @default.
• W4288987527 hasConcept C111113717 @default.
• W4288987527 hasConcept C112705442 @default.
• W4288987527 hasConcept C121608353 @default.
• W4288987527 hasConcept C126322002 @default.
• W4288987527 hasConcept C143998085 @default.
• W4288987527 hasConcept C159654299 @default.
• W4288987527 hasConcept C197934379 @default.
• W4288987527 hasConcept C203014093 @default.
• W4288987527 hasConcept C2779984678 @default.
• W4288987527 hasConcept C2780868878 @default.

• next